Forbion’s Post

We are proud to announce that we have closed a $160.5 million #SeriesC #financing. Proceeds will be used to support clinical development of OBX-115 in ongoing trials, including a multicenter trial for patients with metastatic melanoma and non-small cell lung cancer. The financing rounds was led by new investor, Wellington Management. Additional new investors participating in the financing include Foresite Capital, Janus Henderson Investors, Novo Holdings A/S, Paradigm BioCapital, RTW Investments, funds and accounts advised by T. Rowe Price Associates, Inc., and Woodline Partners LP. Existing investors Atlas Venture, Blue Owl Healthcare Opportunities, Bristol Myers Squibb, Deep Track Capital, Logos Capital, RA Capital Management, TCGX, Samsara BioCapital and Surveyor Capital (a Citadel company) also participated in the financing. Read the full announcement here: https://lnkd.in/eExbpjBU

Great news from CatalYm: we have successfully completed an oversubscribed $150 million Series D #financing to advance our lead program #visugromab into randomized Phase 2b clinical trials. This investment will expand visugromab’s late-stage clinical development into earlier lines of treatment including checkpoint naïve and second-line refractory settings in select #SolidTumor indications. We extend a warm welcome to our new investors: Canaan, Bioqube Ventures, Omega Funds, Forbion Growth Fund and Gilde Healthcare Partners. Together with support from our participating existing investors JEITO, Brandon Capital, Novartis Venture Fund and Vesalius Biocapital III  the funding highlights the potential of visugromab to bring benefit to cancer patients and also values the novel approach of neutralizing GDF-15, a key resistance factor to anti-cancer therapies. Visugromab is a humanized monoclonal antibody targeting GDF-15, a key regulator of immune resistance to #cancer therapies. Our lead candidate has shown impressive results in a recent Phase 1/2a data update presented at #ASCO2024. The results demonstrated that the combination of visugromab and the PD-1 inhibitor nivolumab achieves deep and durable anti-tumor activity, including complete responses, in patients with anti-PD-(L)1 relapsed/refractory solid tumors. Along with the financing, Colleen Feriod Cuffaro, Partner at Canaan, Jon Edwards, Managing Partner at Bioqube Ventures, and Otello Stampacchia, Managing Director and Founder at Omega Funds, will join our Board of Directors, and Stefan Luzi, PhD, Partner at Gilde joins as an Observer. As we enter this next stage of corporate growth, we remain committed to our mission of breaking immunosuppressive barriers and establishing a new benchmark in cancer care. For more details on the financing, visit: https://lnkd.in/dBfHK4sU

When Sanjaya Singh left Johnson & Johnson in 2021, his former colleague Peter Lebowitz paid close attention. “If Sanjaya Singh is doing something, you want to watch it,” Lebowitz said. That new venture, Philadelphia-based Third Arc Bio, launched Tuesday with $165 million from a Series A round led by Vida Ventures and co-led by Cormorant Asset Management, LP and Hillhouse Investment. The money will go toward developing T-cell engagers for cancer and autoimmune diseases. What do you think are the best approaches for autoimmune disease drug development? And which friend or colleague would you follow to a new job? #biotech #pharma #startup #seriesA #venturecapital #fundraising #cancer #oncology #autoimmune #drugdevelopment #Tcell #immunotherapy STAT

Having joined in mid-2023, our CEO Mathai Mammen, M.D., Ph.D., is eager to reshape the #oncology space with our Helicon Therapeutics, a new category of transformative medicines designed to address a large number of traditionally undruggable targets, including protein-protein interactions. Our lead product candidate, FOG-001, is a first-in-class, long-sought after β-catenin:TCF inhibitor, and is in clinical development for patients with #colorectalcancer and other WNT-β-catenin pathway mutation tumors. Read more in the STAT piece written by Allison DeAngelis below. #JPM24

🔬💡 Exciting News! 🌟 AltruBio Inc. Raises $225M in Series B Funding! 💰 Originally known as AbGenomics Holdings, the start-up initially focused on developing cancer drugs. But in 2020, it shifted course, swapped out its leadership and rebranded as AltruBio Inc.. The company raised $63 million in funding a year later, followed by a MASSIVE $225M oversubscribed Series B round earlier this week. The round comes amid a surge of industry interest in developers of immune disease drugs and the financing will help the company advance its ulcerative colitis candidate into mid-stage clinical trials. #AltruBio #Biotech #SeriesB #Innovation #UlcerativeColitis #TransformativeTherapies

Excited to check out the valuable insights at Cambridge VIP: Venture, Innovation & Partnering's Oncology Venture, Innovation & Partnering Summit tomorrow Oct 9-10 in Cambridge produced by Cambridge Innovation Institute! Let me know if you are also attending and want to connect. #oncology #innovation #intellectualproperty #patentlaw #venture #diagnostics #therapeutics #cambridgema #strategy

🔥 𝗗𝗲𝗮𝗹 𝗼𝗳 𝘁𝗵𝗲 𝗪𝗲𝗲𝗸 🔥 #25: iOnctura Raises EUR80M in Series B Financing The funding round was led by Syncona Limited , with contributions from the European Innovation Council Fund and existing investors, including M Ventures, Inkef Capital, Vi Partners, Schroders Capital, and 3B Future Health Fund I & II. The company plans to use the funds to expedite the development of its lead asset, roginolisib, for treating uveal melanoma and various other oncology indications. iOnctura aims to begin trials for additional cancer indications, such as non-small cell lung cancer and primary myelofibrosis, by the end of 2024. 👏 𝘊𝘰𝘯𝘨𝘳𝘢𝘵𝘶𝘭𝘢𝘵𝘪𝘰𝘯𝘴 𝘵𝘰 𝘵𝘩𝘦 𝘦𝘯𝘵𝘪𝘳𝘦 𝘵𝘦𝘢𝘮! News Link ➡️ https://lnkd.in/eyNaCha4 Giusy Di Conza Alessio Bevilacqua David Seeberger Kiran Roest Lars van der Veen Diego Braguglia Thijs Cohen Tervaert Berthold Baurek-Karlic Julia Gülden-Zeisberger Denis Voldman Makar Vergovskiy Iman Saïd Philipp Sakuler #DealMatrix #iOnctura #Startups #DealOfTheWeek #Deals #Investments

𝐀𝐯𝐞𝐧𝐳𝐨 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐑𝐚𝐢𝐬𝐞𝐬 $𝟏𝟓𝟎𝐌 𝐟𝐨𝐫 𝐍𝐞𝐱𝐭-𝐆𝐞𝐧 𝐎𝐧𝐜𝐨𝐥𝐨𝐠𝐲 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 Avenzo Therapeutics, Inc.Avenzo Therapeutics closes oversubscribed $150M Series A-1 financing, totaling $347M since Aug '22 founding. Led by NEA, Deep Track Capital, Sofinnova Investments Sofinnova Partners, & Sands Capital Sands Capital, with participation from new investors like INCE Capital INCE Capital & Delos Capital Delos Capital. Funds will fuel advancement of AVZO-021, a leading cyclin-dependent kinase 2 (CDK2) inhibitor in Phase 1 clinical study for HR+/HER2- metastatic breast cancer & other solid tumors. Athena Countouriotis, M.D. Athena Countouriotis MD, Avenzo's Co-founder, President & CEO, expressed gratitude for the support, highlighting potential with AVZO-021 and expansion of the pipeline. Jakob Dupont, M.D. Jakob Dupont, MD MA, of Sofinnova Investments, joins the Board, bringing extensive oncology experience. #Oncology #Funding #SeriesA #ClinicalTrials #Investment #CancerResearch

Another oncology biotech has submitted its IPO plans. Pennsylvania startup ArriVent BioPharma, valued at $400 million, plans to list on Nasdaq to support its Phase III trial and prepare for commercialization. Its lead lung cancer drug is already marketed in China by Allist Pharmaceuticals. #arrivent #biotech #nasdaq #ipo #initialpublicoffering #drugdevelopment #oncology #oncologytrials #cancerresearch #wallstreet

#fundingalert 💼Company: NextPoint Therapeutics, Inc. 💰Funding: $42.5Million  ⚡Round: Series B 👥Investors: Catalio Capital Management, R. Jacob Vogelstein, MPM BioImpact, Leaps by Bayer, Sixty Degree Capital, Dana-Farber Cancer Institute NextPoint was founded by Ivan Cheung (CEO). The funds will be used to advance the company’s two immuno-oncology clinical programs, NPX267 and NPX887, as well as propel the development of additional #therapeutic modalities in the pipeline that target the novel HHLA2 tumor antigen. NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 axis, also known as B7-H7. Their innovative approach integrates #foundational science with a defined #clinical biomarker strategy to deliver a new class of #monotherapies for patients who do not benefit from PD-1/L1 inhibitors. Read more - https://lnkd.in/gx5rqfVC To share your startup story write us on - contact@startuprise.io #nextPoint #funding #startup